- FDA Approves Sunitinib Malate for Adjuvant Treatment of RCC
- ESMO Asia 2017 Congress: Certificate of Attendance
- ESMO Celebrates Successful Completion of 3rd ESMO Asia Congress in Singapore
- ESMO Asia 2017 Press Release: Global Analysis Looks at Policy Gaps and How to Advance Breast Cancer Control in Asia
- ESMO Asia 2017 Press Release: Osimertinib Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients
- ESMO Asia 2017 Press Release: Study Shows New Second Line Therapy for Metastatic Colorectal Cancer is Effective and Safe
As well as peer-reviewed journals, touchONCOLOGY also provide video interviews, procedures and general updates on the latest trends within the area, as well as featuring carefully selected video from our partners.
Dr Sam H Ahmedzai discusses the use of rolapitant for CINV.
Joe O'Sullivan discusses the role of radium-223 in the mestastatic prostate cancer treatment paradigm. Support: The filming of this video was supported by Bayer. Disclosures: Joe O'Sullivan has participated in Advisory Boards with Bayer, Sanofi and Janssen.
Dr Florian Scotte discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in French. Speaker disclosures: Consultant, speaker or advisory board with: Roche, Vifor, MSD, TEVA, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, AMGEN, Pierre...
Dr Massimo Di Maio discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in Italian. Speaker disclosures: Received honoraria or acted as consultant for Bayer, Eli Lilly, AstraZeneca, Janssen, Bristol Myers Squibb, Merck Sharp...
Dr Pere Gascon discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in Spanish. Filmed at the ESMO annual meeting, 2017
Dr Karin Jordan discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in German. Speaker disclosures: Karin Jordan is a consultant for Tesaro. Filmed at the ESMO annual meeting, 2017
Part 2 of 2 - Dr Ajjai Alva explains checkpoint inhibitors and discusses their use in combination with IL-2 for patients who do not respond to checkpoint inhibitors alone. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 1 of 2 – In our interview with Dr Ajjai Alva, he discusses the importance of histology and performance status in selecting patients for high dose interleukin-2 therapy. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Axel Merseburger, Shaji Kumar, Sharlene Gill, Ahmad Awada, Paolo Ascierto and Maurice Perol discuss their experiences with the European Oncology...
Part 2 of 2 - Dr David Heigener discusses the large number of patients that can’t receive targeted therapy or checkpoint inhibitors, and other unmet needs in non-small cell lung cancer (NSCLC). He also gives us his thoughts on liquid biopsy and its use in NSCLC. Filmed at The American Society of...
Part 1 of 2 – The first part of our interview with Dr David Heigener highlights the lack of data on combination therapies for EGFR-positive non-small cell lung cancer and the issues with synergistic toxicity. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Sharlene Gill discusses the latest developments in pancreatic cancer and the current treatment guidelines. You can read Dr Gill's latest article on pancreatic cancer here
Editorial Board member Bernardo Rapoport talks about his favourite features of European Oncology & Haematology and touchONCOLOGY.com
We are delighted to introduce Axel Merseburger, the new Editor-in-Chief of European Oncology & Haematology.
Paolo Asceirto, from our European editorial board, discusses the challenges and recent advances in the treatment of advanced melanoma.